Announcements Trials

Browse Landscape

Phase

Status

Completed 11 Terminated 6 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 4 Vomiting 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Prostatic Neoplasms 1 Postoperative Nausea and Vomiting 1 Pain, Intractable 1 Oropharyngeal Neoplasms 1 Nausea 1 Lymphoma, Non-Hodgkin 1 Leukemia, Plasma Cell 1 Immunoglobulin Light-chain Amyloidosis 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Cancer Pain 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 27 Rituximab 20 Etoposide 14 Cytarabine 13 Melphalan 11 Vincristine 10 fludarabine 9 Prednisone 9 Doxorubicin 9 Busulfan 8 Peripheral Blood Stem Cell Transplantation 7 Radiotherapy 6 Filgrastim 6 Cyclosporine 6 Bendamustine Hydrochloride 6 fludarabine phosphate 5 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5 Mycophenolic Acid 5 Cisplatin 5 tositumomab I-131 4 ibritumomab tiuxetan 4 Ifosfamide 4 Dexamethasone 4 Carmustine 4 relmacabtagene autoleucel 3 Thiotepa 3 Indium 3 Immunotherapy, Adoptive 3 Gemcitabine 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Lymphoma, Non-Hodgkin × Calcium Dobesilate × Clear all

NCT00324467 2021-07-22

LYTPET

British Columbia Cancer Agency

Phase 2 Unknown

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡